- Dimerix (DXB) partners with the Australian Centre for Accelerating Diabetes Innovations (ACADI) to test its DMX-200 drug in a new clinical trial in patients with diabetic kidney disease
- The company says this trial provides a potential market opportunity in addition to its other Phase 3 trials underway
- The clinical trial protocol is currently being finalised, though Dimerix says it is expected to be a 12- to 24-month study of kidney function in patients with diabetic kidney disease, with an interim analysis
- As part of the study, Dimerix plans to recruit participants from across Australia, and the trial is expected to commence in Q4 2022
- Shares in Dimerix are up 3.13 per cent to 16.5 cents at 10:46 am AEST
Dimerix (DXB) has partnered with the Australian Centre for Accelerating Diabetes Innovations (ACADI) to test its DMX-200 drug in a new clinical trial in patients with diabetic kidney disease.
The company said this trial provided a potential market opportunity in addition to its other Phase 3 trials underway.
The clinical trial protocol is currently being finalised, though Dimerix said it was expected to be a 12- to 24-month study of proteinuria and eGFR (kidney function) in patients with diabetic kidney disease, with an interim analysis. The trial is set to commence in the fourth quarter of 2022.
Under the study, the company plans to recruit participants from across Australia.
ACADI Centre Director Associate Professor Elif Ekinci said the partnership would focus on finding new and potentially more effective treatments for people living with diabetic kidney disease, which was an area of unmet need.
“Diabetes is the key cause of kidney disease leading to dialysis and need for transplantation,” Professor Ekinci said.
“Unfortunately, diabetic kidney disease is one of the most difficult complications of diabetes to treat and comes at a massive cost to the person living with diabetes and to our health care systems.
“ACADI is pleased to see innovative therapies being researched and developed in an area of unmet need.”
ACADI was established in January 2022 through the Australian government’s Medical Research Future Fund (MRFF) from the Targeted Translation Research Accelerator program, delivered by MTPConnect.
The centre was awarded $10 million over four years from the MRFF in addition to $13.3 million in cash and in-kind contributions from 70 partners across the country.
Shares in Dimerix were up 3.13 per cent to 16.5 cents at 10:46 am AEST.